LUNG Relative Valuation
LUNG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LUNG is overvalued; if below, it's undervalued.
Historical Valuation
Pulmonx Corp (LUNG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -12.19. The fair price of Pulmonx Corp (LUNG) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.14
Fair
-1.53
PE
1Y
3Y
5Y
Trailing
Forward
-1.14
EV/EBITDA
Pulmonx Corp. (LUNG) has a current EV/EBITDA of -1.14. The 5-year average EV/EBITDA is -12.46. The thresholds are as follows: Strongly Undervalued below -41.49, Undervalued between -41.49 and -26.97, Fairly Valued between 2.06 and -26.97, Overvalued between 2.06 and 16.57, and Strongly Overvalued above 16.57. The current Forward EV/EBITDA of -1.14 falls within the Historic Trend Line -Fairly Valued range.
-1.00
EV/EBIT
Pulmonx Corp. (LUNG) has a current EV/EBIT of -1.00. The 5-year average EV/EBIT is -10.77. The thresholds are as follows: Strongly Undervalued below -35.67, Undervalued between -35.67 and -23.22, Fairly Valued between 1.68 and -23.22, Overvalued between 1.68 and 14.13, and Strongly Overvalued above 14.13. The current Forward EV/EBIT of -1.00 falls within the Historic Trend Line -Fairly Valued range.
0.86
PS
Pulmonx Corp. (LUNG) has a current PS of 0.86. The 5-year average PS is 10.87. The thresholds are as follows: Strongly Undervalued below -12.12, Undervalued between -12.12 and -0.62, Fairly Valued between 22.37 and -0.62, Overvalued between 22.37 and 33.87, and Strongly Overvalued above 33.87. The current Forward PS of 0.86 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Pulmonx Corp. (LUNG) has a current P/OCF of 0.00. The 5-year average P/OCF is -7.77. The thresholds are as follows: Strongly Undervalued below -38.12, Undervalued between -38.12 and -22.95, Fairly Valued between 7.41 and -22.95, Overvalued between 7.41 and 22.59, and Strongly Overvalued above 22.59. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-2.87
P/FCF
Pulmonx Corp. (LUNG) has a current P/FCF of -2.87. The 5-year average P/FCF is -10.84. The thresholds are as follows: Strongly Undervalued below -36.20, Undervalued between -36.20 and -23.52, Fairly Valued between 1.85 and -23.52, Overvalued between 1.85 and 14.53, and Strongly Overvalued above 14.53. The current Forward P/FCF of -2.87 falls within the Historic Trend Line -Fairly Valued range.
Pulmonx Corp (LUNG) has a current Price-to-Book (P/B) ratio of 1.47. Compared to its 3-year average P/B ratio of 2.65 , the current P/B ratio is approximately -44.45% higher. Relative to its 5-year average P/B ratio of 3.82, the current P/B ratio is about -61.48% higher. Pulmonx Corp (LUNG) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -17.03%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -12.16% , the current FCF yield is about -100.00% lower.
1.47
P/B
Median3y
2.65
Median5y
3.82
-41.78
FCF Yield
Median3y
-17.03
Median5y
-12.16
Competitors Valuation Multiple
The average P/S ratio for LUNG's competitors is 0.00, providing a benchmark for relative valuation. Pulmonx Corp Corp (LUNG) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 5.47%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LUNG decreased by 68.48% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 20.39M to 21.50M.
The secondary factor is the Margin Expansion, contributed -6.44%to the performance.
Overall, the performance of LUNG in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Pulmonx Corp (LUNG) currently overvalued or undervalued?
What is Pulmonx Corp (LUNG) fair value?
How does LUNG's valuation metrics compare to the industry average?
What is the current P/B ratio for Pulmonx Corp (LUNG) as of Dec 05 2025?
What is the current FCF Yield for Pulmonx Corp (LUNG) as of Dec 05 2025?
What is the current Forward P/E ratio for Pulmonx Corp (LUNG) as of Dec 05 2025?